Do affluent societies have the only options for the best therapy?
Open Access
- 21 February 2007
- journal article
- editorial
- Published by Springer Nature in Leukemia
- Vol. 21 (3) , 387-388
- https://doi.org/10.1038/sj.leu.2404534
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- Hematopoietic stem cell transplants for chronic myeloid leukemia in Europe—Impact of cost considerationsLeukemia, 2007
- The early referral for reduced-intensity stem cell transplantation in patients with Ph1 (+) chronic myelogenous leukemia in chronic phase in the imatinib era: results of the Latin American Cooperative Oncohematology Group (LACOHG) prospective, multicenter studyBone Marrow Transplantation, 2005
- Blood and marrow transplantation compensation: Perspective in payer and provider relationsTransplantation and Cellular Therapy, 2004
- Availability and Appropriateness of Allogeneic Bone Marrow Transplantation for Chronic Myeloid Leukemia in 10 CountriesNew England Journal of Medicine, 1994
- Transplanted Technology: Third World Options and First World ScienceNew England Journal of Medicine, 1987